A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Cognition Therapeutics is advancing CT1812, a novel oral treatment targeting synaptic density in patients with mild to moderate Alzheimer's disease. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. With a focus on synaptic health, CT1812 may differentiate itself from existing treatments by addressing cognitive decline through a unique mechanism. Competitive analysis indicates a crowded landscape with several anti-amyloid and tau-targeting therapies; however, CT1812's distinct approach may provide a strategic advantage. Diligence considerations should include the safety profile, regulatory pathway, and potential for partnerships or licensing agreements, particularly given the involvement of the National Institute on Aging (NIA) as a collaborator.
Indication: Alzheimer Disease
Modality: small molecule
Target: Synaptic Vesicle Glycoprotein 2A (SV2A)
Sponsor: Cognition Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Synaptic Vesicle Glycoprotein 2A (SV2A)
View original source fields
Condition raw: Alzheimer Disease
Condition normalized: Alzheimer Disease
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Synaptic Vesicle Glycoprotein 2A (SV2A)
Target normalized: Synaptic Vesicle Glycoprotein 2A (SV2A)